Xeris Biopharma Holdings (XERS) Total Current Liabilities (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Total Current Liabilities data on file, last reported at $118.6 million in Q1 2026.

• Quarterly Total Current Liabilities rose 24.74% year-over-year to $118.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.6 million (up 24.74% YoY) and the FY2025 annual result came in at $109.6 million, up 9.09% from the prior year.
• Total Current Liabilities climbed to $118.6 million in Q1 2026, from $109.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $118.6 million in Q1 2026 to a low of $64.5 million in Q2 2022.
• A 5-year average of $87.7 million and a median of $87.0 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 83.88% — and 2024, when it fell 10.24%.
• Tracing XERS's Total Current Liabilities over 5 years: stood at $73.6 million in 2022, then advanced by 29.3% to $95.2 million in 2023, then increased by 5.52% to $100.4 million in 2024, then increased by 9.09% to $109.6 million in 2025, then rose by 8.23% to $118.6 million in 2026.
• The last three Total Current Liabilities figures came in at $118.6 million (Q1 2026), $109.6 million (Q4 2025), and $116.2 million (Q3 2025), per Business Quant data.